Expert Point of View: Marjorie G. Zauderer, MD and Andrew D. Seidman, MD
Commenting on the ganetespib study, Marjorie G. Zauderer, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center in New York, said that this first-in-class study suggests efficacy and represents a potential advance in lung cancer treatment. “We haven’t had any advances in a long time. We await the results of the phase III trial,” she said.
Andrew D. Seidman, MD, another medical oncologist from Memorial Sloan-Kettering Cancer Center, said that heat shock protein 90 inhibitors are also being studied in breast cancer and other cancers. “This approach of harnessing a chaperone protein is applicable to other tumor types,” he stated. ■
Disclosure: Drs. Zauderer and Seidman reported no potential conflicts of interest.
First Positive Trial of Heat Shock Protein 90 Inhibitor in Lung Cancer That Has Progressed after First-line Therapy
The investigational heat shock protein (Hsp)90 inhibitor ganetespib plus docetaxel extended overall survival compared with docetaxel alone as second-line therapy in patients with advanced non–small cell adenocarcinoma of the lung that had progressed on first-line therapy in the randomized phase II...